Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 926-932

  Pacini, F ^a,b   Ladenson, P W ^c   Schlumberger, M ^d   Driedger, A ^e   Luster, M ^f   Kloos, R T ^g   Sherman, S ^h   Haugen, B ⁱ   Corone, C ^j   Molinaro, E ^a   Elisei, R ^a   Ceccarelli, C ^a   Pinchera, A ^a   Wahl, R L ^c   Leboulleux, S ^d   Ricard, M ^d   Yoo, J ^k   Busaidy, N L ^h   Delpassand, E ^h   Hanscheid, H ^f   Felbinger, R ^f   Lassmann, M ^f   Reiners, C ^f   more..

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j CENTRE RENÉ HUGUENIN   (France)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; COLD TOLERANCE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; PERIORBITAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TASTE DISORDER; THYROID CARCINOMA; THYROID GLAND; THYROTROPIN RELEASE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33644816884     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1651     Document Type: Article

References (27)

1. Schlumberger MJ 1998 Medical progress: papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
2. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 A systemic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676
3. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Lambert E, Jarzab B, Jamar F, Duntas L, Cohen G 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105-112
4. Bal CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S 2004 Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? Thyroid 14:217-225
5. Dow KH, Ferrell BR, Anello C 1997 Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7:613-619
6. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, De-Groot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon III HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
7. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A 2002 Ablation of thyroid residues with 30 mCi 131-I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068
8. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115
9. Robbins RJ, Larson SM, Sinha N, Divgi C, Pentlow KS, Ghossein R, Tuttle RM 2002 A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 43:1482-1488
10. International Union Against Cancer (UICC), Sobin LH, Wittekind Ch, eds. 1997 TNM classification of malignant tumours. 5th ed. New York: John Wiley, Sons, Inc.
11. Luster M, Sherman S, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, Reiners C 2003 Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone (rhTSH) and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30:1371-1377
12. Lassmann M, Luster M, Hanscheid H, Reiners C 2004 The impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45:619-625
13. Hänscheid H, Lassmann M, Luster M, Thomas RT, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Richard M, Driedger A, Kloos RT, Sherman SI, Haugen B, Carriere V, Corone C, Reiners C, Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med, in press
14. Akabani G, Poston Sr JW 1991 Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides. J Nucl Med 32:830-834
15. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, Carayon P, Ericsson UB, Koutras DA, Lamas de Leon L, DeNayer P, Pacini F, Palumbo G, Santos A, Schlumberger M, Seidel C, Van Herle AJ, De Vijlder JJM 1996 Human thyroglobulin reference material (CRM 457). 2nd part: physicochemical characterization and certification. Ann Biol Clin (Paris) 54:343-348
16. Benotti J, Benotti N, Pino S, Gardyna H 1965 Determination of total iodine in urine, stools, diets and tissue. Clin Chem 11:932-936
17. Blackwelder WC 1982 "Proving the null hypothesis" in clinical trials. Control Clin Trials 3:345-353
18. Johansen K, Woodhouse NJY, Odugbesan O 1991 Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 32:252-254
19. Bal CS, Kumar A, Pant GS 2004 Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89:1666-1673
20. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896
21. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673
22. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501
23. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic 131-iodine scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178
24. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441
25. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after ablation? J Clin Endocrinol Metab 87:1490-1498
26. Maxon III HR, Smith HS 1990 Radioiodine-131 in the diagnosis and treatment of well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19:685-718
27. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644